paladin, you say "If the Covid trial pans out in a very strong way then there is a greater chance for a buyout scenario in advance of or during the BoM2 trial.....one would think."

Based on what Don said (refer to dictation by imtesty): "And again it builds towards what our main event is. COVID hopefully will be gone in a few years. Our drug approach with the anti-inflammatory works on all variants. So we do feel that this is a unique approach, but it will prep the market for our main program. 25% of all patients who finish with COVID are left with some form of new cardiovascular disease. 30% are left with diabetes for the first time. So this is a program that will lead very nicely into our main program, which starts out commercially hopefully in about two to three years."

The last sentence above (as I understand) certainly indicates that Don has no intention to sell off RVX. The COVID program with Eversana will lead nicely into the main program which starts commercially in 2-3 years that being BOM2. I could be wrong!

Koo